Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed /.
SAN DIEGO, April 03, 2024 Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell -derived cellular.
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light.
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high.